<DOC>
	<DOCNO>NCT01536379</DOCNO>
	<brief_summary>Kidney transplantation best treatment many patient kidney failure . Sometimes transplanted kidney reject patient 's immune system . Many type immune system cell , include B cell , active rejection . B cell produce antibody anything body see non-self , like germ transplant kidney . Most medicine help prevent transplant rejection affect cell B cell . Belimumab medication use treat disease call lupus . Belimumab slow development antibody-producing B cell . This study test whether belimumab work part immune system cause rejection . Twenty thirty adult get kidney transplant study . Like flip coin , computer randomly assign half give belimumab half give placebo ( fake medicine ) . Patients doctor know medicine assign study . A total 7 dos study medicine give vein . One dose give transplant surgery , 6 give 2 , 4 , 8 , 12 , 16 20 week transplant surgery . Usual transplant medicine also give . After dos give , patient watch tested 24 , 36 , 52 week transplant surgery . Blood sample test see study medicine immune system transplant patient . If patient get kidney biopsy , sample test see belimumab effect . Patients ask many question see side effect . The study do Addenbrooke 's Hospital Cambridge Guys &amp; St Thomas Hospital London , United Kingdom . A pharmaceutical company , GlaxoSmithKline , funding study .</brief_summary>
	<brief_title>A Study Belimumab Prevention Kidney Transplant Rejection</brief_title>
	<detailed_description />
	<mesh_term>Belimumab</mesh_term>
	<criteria>Eligible kidney transplantation : Considered eligible transplantation undergo multidisciplinary evaluation institution transplantation perform Donor characteristic : Receiving decease donor kidney live donor kidney allograft Age &amp; Gender : Male female 18 75 year age , inclusive , time signing informed consent Female Subjects : Not pregnant nursing least one follow condition apply : a. Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy postmenopausal define 12 month spontaneous amenorrhea . In absence confirmatory laboratory assessment [ ( blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 million international unit per milliliter ( MIU/mL ) estradiol &lt; 40 picogram per milliliter ( pg/mL ) ( &lt; 147 picomole per liter [ pmol/L ] ) ] questionable case , female subject require use one contraception method describe investigator designee , confirmatory result become available ; b . Questionable postmenopausal status agree use one contraception method describe investigator designee , Day 0 16 week last dose investigational product postmenopausal status confirm blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MIU/mL estradiol status use hormone replacement therapy ( HRT ) require use one contraception method describe investigator designee , postmenopausal status confirm . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ; c. Childbearing potential agrees use one contraception method describe investigator designee , Day 0 16 week last dose investigational product . Liver function ( recent value available transplantation ) : alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Immunosuppressants : time transplantation , plan receive combination immunosuppressant include basiliximab , mycophenolate mofetil , tacrolimus , prednisolone Donor characteristic : receive kidney allograft donor follow characteristic : ) cold ischemic time exceed 36 hour ; b ) age &lt; 5 year old ; c ) donor brain death ( DBD ) , age &gt; 70 year old ; ) donor cardiac death ( DCD ) age &gt; 70 year old ; e ) ABO blood type incompatible recipient ; f ) 0 0 0 HLAA B DR mismatch recipient National Health Service Blood Transplant ( NHSBT criterion ; g ) T and/or Bcell positive crossmatch complement dependent cytotoxicity flow cytometry recipient . Note : ( In situation may preexist T and/or Bcell positive crossmatch complement dependent cytotoxicity flow cytometry recipient fully reveal immediately transplant ; situation record meet exclusion criterion withdraw involvement study ; h ) serology positive hepatitis B ( except hepatitis B surface antibody prior vaccination ) , hepatitis C human immunodeficiency virus ( HIV ) Transplant kidney : previously receive hematopoietic stem cell/marrow transplant organ transplant kidney ( exception corneal transplantation ) Planned immunosuppressant regimen : consider steroidfree alemtuzumab induction Prior therapy time : ever receive following : ) Bcell target therapy ( e.g. , rituximab , antiCD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] , BLySreceptor fusion protein [ BR3 ] , TACI fragment , crystallizable ( Fc ) , belimumab ) 364 Day prior therapy : receive follow within 364 day Day 0 : ) Cyclophosphamide ; b ) Abatacept ; c ) A biologic investigational agent Bcell target therapy [ e.g. , abetimus sodium , anti CD40L antibody ( e.g. , BG9588/ IDEC 131 ; investigational agent applies drug approve sale country use ] 90 Day prior therapy : receive follow within 90 day Day 0 : ) Anti Tumor necrosis factor ( TNF ) antiInterleukin ( IL ) 6 therapy ( e.g. , adalimumab , etanercept , infliximab , tocilizumab ) ; b ) Interleukin1 receptor antagonist ( e.g. , anakinra ) ; c ) Intravenous immunoglobulin ( IVIG ) ; ) Plasmapheresis , leukapheresis 60 Day prior therapy : receive follow within 60 day Day 0 : ) A nonbiologic investigational agent ( investigational agent applies drug approve sale country use ) ; b ) Any new immunosuppressive/immunomodulatory agent ; tacrolimus , Mycophenolate mofetil ( MMF ) , corticosteroid permit . Inhaled steroids new topical immunosuppressive agent ( e.g. , eye drop , topical cream ) also allow . 30 Day prior therapy : receive follow within 30 day Day 0 : ) A live vaccine ; b ) An increase dose immunosuppressive/immunomodulatory agent ( decrease dose discontinuation permit ) . Increases dos tacrolimus , MMF , corticosteroid permit . Malignancy : history malignancy past 5 year except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Acute chronic infection : require management acute chronic infection ( excludes prophylaxis infection ) , follow : ) Currently receive suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) , , opinion investigator , could put subject undue risk ; b ) Hospitalized treatment infection within 30 day Day 0 , , opinion investigator , could put subject undue risk ; c ) Treated infection parenteral ( intravenous intramuscular ) ] antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 30 day Day 0 , , opinion investigator , could put subject undue risk Other disease/conditions : following : ) clinical evidence significant unstable uncontrolled acute chronic disease ( i.e. , cardiovascular , pulmonary , hematologic , gastrointestinal , hepatic , neurological , malignancy infectious disease ) , opinion investigator , could confound result study put subject undue risk ; b ) surgical procedure plan 6 month Day 0 , kidney transplantation related procedure ; c ) know history medical disease ( e.g. , cardiopulmonary ) , laboratory abnormality , condition ( e.g. , poor venous access ) , opinion investigator , make subject unsuitable study Hepatitis : know serologic evidence hepatitis B infection base result test hepatitis B surface antigen ( HBsAg ) , antibodies hepatitis B core antigen ( HBc ) and/or hepatitis B surface antigen ( HBs ) follow : ) Patients positive HBsAg exclude ; ) Patients negative HBsAg antiHBc antibody positive antiHBs antibody history hepatitis B vaccination exclude ; c ) Patients negative HBsAg positive antiHBc antiHBs antibody exclude ; ) Patients negative HBsAg antiHBs antibody positive antiHBc antibody exclude ; e ) Or know serologic evidence hepatitis C infection base result test hepatitis C antibody hepatitis C recombinant immunoblot assay ( RIBA ) follow : Patients positive test Hepatitis C antibody confirm sample Hepatitis C RIBA immunoblot assay . Patients positive Hepatitis C antibody , negative Hepatitis C RIBA immunoblot assay perform sample , eligible participate . Patients positive Hepatitis C antibody positive indeterminate result Hepatitis C RIBA immunoblot assay perform sample , eligible participate . HIV : know historically positive HIV test test positive screen HIV . Immunodeficiency : recipient history immunodeficiency ( define Immunoglobulin A isotype ( IgA ) level &lt; 10 milligram per deciliter ( mg/dL ) Immunoglobulin G isotype ( IgG ) level &lt; 400 mg/dL ) . Laboratory abnormality : abnormal laboratory assessment , judge clinically significant investigator . Lymphopenia : lymphocyte count &lt; 500/ millimeter ( mm ) ^3 . Drug Sensitivity : history sensitivity study medication , component thereof history drug allergy include previous anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody , opinion investigator Medical Monitor , contraindicate participation . Substance abuse : evidence current drug alcohol abuse dependence . Blood donation : participation study would result donation blood blood product excess 700 mL within 56day period Venous access : venous access limitation likely preclude monthly infusion Compliance : unlikely comply schedule study visit base investigator judgment history substance abuse , psychiatric disorder condition may compromise communication investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Infection</keyword>
	<keyword>Quality Life</keyword>
</DOC>